S-1: Profusa Secures $100M Equity Facility, Shifts to Bitcoin

Profusa, Inc. has entered into a committed equity facility of up to $100 million with Ascent Partners Fund LLC, with proceeds primarily intended for Bitcoin purchases, as it continues development of its biointegrated sensor platforms amidst significant financial challenges.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination with Profusa, Inc. (California corporation) on July 11, 2025, becoming a wholly-owned subsidiary.
• The company is a clinical-stage digital health and medical technology firm developing biointegrated sensors, including the Lumee Oxygen Platform and Lumee Glucose Platform.
• The Lumee Oxygen Platform received CE Mark approval in Europe on January 14, 2020, and commercialization in Europe is anticipated to begin in early 2026.
• The Lumee Glucose Platform, a continuous glucose monitor (CGM), has shown promising clinical data with a Mean Absolute Relative Difference (MARD) of approximately 11% and up to nine months of functionality post-injection, with zero device-related serious adverse events in 54 subjects.
• Regulatory submission for Lumee Glucose is anticipated in early 2026, with U.S. approval targeted for late 2026 or early 2027.
• A Purchase Agreement was signed with Ascent Partners Fund LLC on July 28, 2025, allowing Profusa to sell up to $100,000,000 of common stock to Ascent over 36 months.
• Proceeds from this equity facility will be used primarily for Bitcoin purchases, provided the company's cash balance exceeds $5,000,000; otherwise, proceeds will first be allocated to reach that cash balance.
• Profusa incurred a net loss of $2.7 million for the three months ended March 31, 2025, and $9.2 million for the year ended December 31, 2024.
• As of March 31, 2025, cash and cash equivalents were less than $0.01 million.
• The company has substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional funding.
• Total common stock outstanding as of July 30, 2025, is 32,788,877 shares.
• The filing registers 8,970,830 shares for resale by Ascent, comprising 8,070,830 Purchase Shares and 900,000 Commitment Warrant Shares.
• The Commitment Warrants have an exercise price of $0.01, and the number of underlying shares will be reduced to 450,000 if Profusa does not require Ascent to purchase any Purchase Shares within 100 days.
• The purchase price per share for sales to Ascent will be 97% of the lowest volume-weighted average price (VWAP) during a 10-day valuation period, subject to a floor price.
• Ascent's beneficial ownership is limited to 9.99% of outstanding shares.
• Profusa holds a significant intellectual property portfolio with 20 issued U.S. patents and 80 rest-of-world patents, expiring between March 2030 and January 2040.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including recurring significant losses, a substantial working capital deficit, and an explicit 'going concern' warning from its auditors. The recent Nasdaq delisting further exacerbates liquidity and investor confidence issues. While a new committed equity facility provides a potential lifeline, its proceeds are primarily allocated to highly volatile Bitcoin purchases, introducing extreme and unpredictable risk to the balance sheet. The core products are still in early commercialization or clinical trial stages with no guaranteed regulatory approval or market acceptance. Existing debt defaults and the overall high-risk profile make this a highly speculative investment with significant near-term downside potential, despite long-term technological promise.

Positives

• Secured a committed equity facility of up to $100 million, providing a potential source of funding for operations and strategic initiatives.
• Lumee Oxygen Platform has received CE Mark approval in Europe, enabling anticipated commercialization in early 2026.
• Lumee Glucose Platform shows promising clinical data with a Mean Absolute Relative Difference (MARD) of approximately 11% and extended functionality of up to nine months, with no device-related serious adverse events reported.
• The company possesses a robust intellectual property portfolio, including 20 issued U.S. patents and 80 international patents, protecting its core technologies.
• Strategic focus on high-value clinical applications like wound care and diabetes management, with potential expansion into high-growth healthcare sectors such as telemedicine and health & wellness coaching.
• Management believes its technology offers competitive advantages in terms of user-friendliness (hypodermic needle injection vs. surgical implantation) and cost-effectiveness compared to existing CGM solutions.
• The Lumee system's reusable reader component is designed to lower overall system costs, enhancing marketability.
• The company has attracted significant investment from sophisticated venture investors and research institutions, including approximately $30 million from DARPA and NIH.
• Ongoing discussions for an APAC Joint Venture could provide access to Asian markets and an additional $6 million in funding.

Negatives

• The company has incurred significant net operating losses and negative operating cash flows since inception, raising substantial doubt about its ability to continue as a going concern.
• As of March 31, 2025, the company had a very low cash balance of less than $0.01 million.
• Promissory notes totaling $925,000 and a PPP loan of $1.379 million are currently in default due to non-payment.
• The Lumee Glucose Platform is still an investigative product and has not yet received regulatory approval for commercial sale in any jurisdiction.
• The Lumee Oxygen Platform is not yet approved for commercial sale in the U.S.
• The company operates in a highly competitive market with larger, well-established companies possessing greater resources.
• Identified material weaknesses in internal control over financial reporting, including issues with segregation of duties, accounts payable/accrued liabilities review, and valuation of convertible promissory notes/warrants.
• The company's securities were delisted from the Nasdaq Global Market on December 20, 2024, and now trade on the OTC Pink Markets, which can negatively impact liquidity and investor confidence.
• The primary intended use of proceeds from the committed equity facility is to purchase Bitcoin, a highly volatile asset, introducing significant financial risk and potential for substantial losses.
• The U.S. government holds an irrevocable, non-exclusive, royalty-free license and 'march-in rights' on certain of Profusa's patents due to prior government funding, potentially forcing the company to license its inventions to competitors.

Risks

• Inability to predict the actual number of shares sold under the Purchase Agreement or the resulting gross proceeds.
• Significant dilution to existing stockholders from the sale and issuance of common stock to the Selling Stockholder, and potential stock price decline due to actual or perceived sales.
• Investors purchasing ELOC Shares from the Selling Stockholder at different times may pay different prices and experience varying levels of dilution.
• The primary use of proceeds for Bitcoin purchases exposes the company to extreme price volatility and the risk of substantial financial losses.
• Substantial doubt about the company's ability to continue as a going concern, which may hinder future financing efforts.
• Limited operating history and expectation of continued significant losses for several years.
• Intense competition from large, well-established companies with greater financial and human resources.
• Vulnerability to supply disruptions, suboptimal quality, and price fluctuations due to reliance on third-party suppliers and outsourcing.
• No guarantee of FDA 510(k) clearance or PMA approval for products, which could adversely affect business growth.
• Potential for products to cause adverse medical events or be subject to failures/malfunctions requiring FDA reporting, leading to sanctions or recalls.
• Changes to the regulatory landscape may impact the ability to obtain marketing authorization for future product developments.
• Failure to comply with laws, regulations, and contract requirements related to healthcare reimbursement.
• Exposure to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security (e.g., HIPAA, CCPA, GDPR).
• Cybersecurity risks and cyber incidents could compromise confidential data or critical systems, leading to harm to customers, remediation expenses, and litigation.
• Risk of claims of infringement or misappropriation of intellectual property rights of others, potentially leading to shipping prohibitions, licensing requirements, or monetary damages.
• Inability to adequately protect intellectual property rights globally, allowing competitors to produce similar products.
• Lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Potential inability to obtain necessary licenses from third parties on commercially reasonable terms.
• Non-compliance with procedural requirements for patent protection could reduce or eliminate patent rights.
• Inadequate patent term extension or data exclusivity for any product candidates developed as drug products.
• Inability to successfully maintain effective internal control over financial reporting, potentially leading to inaccuracies in financial information and adverse impact on stock price.
• Environmental, social, and corporate governance (ESG) regulations may increase supply chain complexity and affect customer relationships.
• Uncertainty in domestic and global economic and political conditions, including the impact of conflicts like Russia-Ukraine and Israel-Hamas, could adversely affect product demand and operations.
• Changes in financial accounting standards or taxation rules may cause unexpected revenue/expense fluctuations.
• Risks related to the custody of Bitcoin, including loss or destruction of private keys, cyberattacks, and potential reclassification of Bitcoin as a security.
• The company's Nasdaq delisting could result in limited market quotations, reduced liquidity, and difficulty in raising future financing.
• Future sales or the perception of future sales by shareholders could cause the market price to decline.
• The grant and future exercise of registration rights may adversely affect the market price.
• Issuance of additional shares of common stock or other equity securities without stockholder approval would dilute ownership interests.
• Anti-takeover provisions in the company's charter and Delaware law could make an acquisition more difficult.
• Exclusive forum provisions may limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Potential for securities litigation, which is expensive and could divert management attention.
• U.S. government's irrevocable, non-exclusive, royalty-free license and 'march-in rights' on certain patents due to government funding could compel the company to license its inventions to third parties, including competitors, impacting market exclusivity and profitability.

Future Outlook

The company expects to continue incurring significant losses for several years as it scales operations, develops new products, and expands internationally. It anticipates initiating Lumee Oxygen commercialization in Europe in early 2026 and launching it in the U.S. in late 2026, subject to regulatory approval. The next Lumee Glucose validation study is expected to start in the first half of 2026, with regulatory submission in early 2026 and U.S. approval targeted for late 2026 or early 2027. The company plans a dual commercial strategy for Lumee Glucose, targeting both direct-to-hospital and direct-to-pharmacy sales. It aims to continue discussions for an APAC Joint Venture and explore developing sensors for other analytes. The company expects to incur additional expenses as a public entity and may require further financing, with proceeds from the new equity facility primarily directed towards Bitcoin purchases.

Management Comments

• "Management believes the Company's sources of liquidity will be sufficient to fund the Company's planned operations and existing obligations within one year after the date that the consolidated financial statements are issued."
• "Management is targeting the European market (those jurisdictions that accept CE mark) for early launch for both Lumee Oxygen and Lumee Glucose."
• "We feel a difference between other insertable or implantable CGMs and Lumee Glucose, is that the latter can be simply inserted with a hypodermic needle and does not require a surgical implantation, similar to how pharmacists use these needles to administer flu shots and other vaccines."
• "Profusa believes that its technological approach may create advantages to current glucose monitoring solutions on the market to substantially increase the number of users who can benefit from this data stream from the current type 1 diabetes population to the much larger type 2 and pre-diabetes populations, as well as any individuals outside of these aforementioned populations interested in having access to long-lasting continuous glucose data."
• "Profusa believes that Lumees biosensor and artificial intelligence platform compares very attractively with some of the largest products in this market sector."
• "Profusa believes its validated core technology can easily bridge the gap that exists in the current technology landscape for monitoring real time biochemistry."
• "Profusa believes that, at scale, the data Profusas platform generates from its initial products will be a key enabler for the productivity and business models for both of these sectors to expand and reach more of their full potential."
• "Profusa believes its technology could ultimately be that enabling data stream to these other high-growth healthcare sectors."
• "Profusa believes that its solution could benefit those in the type 2 and pre-diabetes populations to both potentially broaden the product reach beyond the currently available solutions, but also generate a broad set of clinical data across a large heterogeneous population to inform the clinical science behind diabetes care throughout the disease spectrum."
• "Profusa believes that its ability to develop products to measure other analytes and expand our product portfolio is enhanced while maintaining the key value propositions of the platform."

Industry Context

The company operates in the highly competitive medical device industry, specifically targeting oxygen monitoring and continuous glucose monitoring (CGM) markets. It faces competition from large, established players like Abbott Laboratories, Medtronic, and Roche. The broader healthcare industry is trending towards technology-enabled solutions for real-time data, shifting clinical decisions from hospitals to home settings, as evidenced by the doubling of the telemedicine market (from $41 billion to over $80 billion from 2019-2021) and growth in remote coaching platforms (to nearly $14 billion). The Centers for Medicare & Medicaid Services (CMS) has introduced reimbursement codes for remote patient monitoring (RPM), providing a tailwind for such technologies. The addressable market for critical limb ischemia is estimated at 5 million patients in the U.S. and EU, while the diabetes market (including pre-diabetics) is projected to reach over 500 million patients in the U.S. and EU by the end of 2025. The CGM market is estimated at $2.8 billion in the U.S. and $800 million in Europe by end of 2024, with the oxygen monitoring market at $2 billion in the U.S. and $700 million in Europe.

Comparison to Industry Standards

• Lumee Glucose's potential for Mean Absolute Relative Difference (MARD) of approximately 11% and functionality up to nine months post-injection compares favorably to current short-term needle-type CGMs requiring weekly sensor replacement.
• The Lumee Glucose system's design for simple subcutaneous injection via a hypodermic needle offers a less invasive deployment procedure compared to some longer-term solutions requiring surgical implantation (e.g., Senseonics Eversense E3, which requires surgical implantation for its 12-month sensor).
• The Lumee Oxygen Platform provides a direct measure of oxygen availability in interstitial fluid, differentiating it from technologies that estimate oxygen saturation in vasculature or provide averaged measurements across large tissue volumes (e.g., transcutaneous oximetry devices like those from Perimed AB, Radiometer Medical, or SenTec AG).
• The company believes its technology offers competitive pricing and low production costs, aiming to break down economic barriers for broader adoption compared to existing high-cost CGM solutions that often limit insurance reimbursement to the most brittle Type 1 and Type 2 diabetes patients.

Management Changes

Corporate Governance

Legal Proceedings

• Currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million accrued.
• No other currently pending legal proceedings are expected to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• Investor Rights Agreement, Voting Agreement, and Right of First Refusal and Co-Sale Agreement will terminate upon the closing of the merger.
• Entered into a Binding Term Sheet for an APAC Joint Venture with Carbis Bay Limited, BC hSensor Limited, and Tasly (International) Healthcare Capital Company Limited, where Tasly Holding Group Co. Ltd. or its affiliates would purchase 60% of the JV for $6 million.
• Has a short-term loan agreement (Tasly Convertible Debt) with Tasly (International) Healthcare Investment & Development Company Limited (a shareholder), with up to $1.6 million borrowed at 12% interest (24% upon default); these loans are currently in default.
• Promissory notes totaling $925,000 (as of March 31, 2025) were issued to founders and insiders, and are currently in default.
• Granted stock options to executive officers and certain directors as part of compensation.
• NorthView Sponsor I, LLC (an affiliate of officers) received $5,000 per month for administrative services until June 30, 2023.
• NorthView Sponsor I, LLC provided a Convertible Working Capital Promissory Note to NorthView, with $1,919,796 principal outstanding as of March 31, 2025, convertible into common stock at $2.22 per share at the sponsor's election.
• Profusa advanced funds to NorthView for operating expenses, with $1,176,565 owed as of March 31, 2025.

Stakeholder Impact

• Shareholders face significant potential dilution from the committed equity facility and future capital raises, as well as increased stock price volatility due to the Bitcoin treasury strategy and recent Nasdaq delisting.
• Employees may experience continued investment in R&D and commercial infrastructure, but also potential workforce instability and intense competition for skilled personnel.
• Customers could benefit from the development and commercialization of new, user-friendly biointegrated sensors (Lumee Oxygen, Lumee Glucose) designed to improve health outcomes, but face risks of product recalls or safety issues.
• Creditors holding promissory notes and the PPP loan are impacted by the company's current default status on these obligations, indicating repayment risk.

Next Steps

• Initiate commercialization of the Lumee Oxygen Platform in Europe in early 2026.
• Conduct U.S. study for Lumee Oxygen for FDA marketing authorization, with submission planned for late 2026.
• Start the next validation study for Lumee Glucose in the first half of 2026.
• Submit for regulatory approval for Lumee Glucose in early 2026, targeting U.S. approval in late 2026 or early 2027.
• Continue discussions with potential partners in Asia to establish the APAC Joint Venture.
• Explore and develop sensors for additional analytes such as lactate, CO2, ethanol, and pH.
• Strategically engage in commercial B2B relationships to provide data streams to telemedicine and health & wellness coaching sectors.
• Finalize accounting conclusions on the Ascent warrants for the upcoming September 30, 2025 financial statements.
• File additional registration statements under the Securities Act for resale of common stock by Ascent if needed to reach the $100 million aggregate purchase commitment.
• Obtain stockholder approval to issue shares in excess of the 19.9% Nasdaq Exchange Cap if the average price for shares purchased by Ascent is below $0.68 per share.
• Remediate identified material weaknesses in internal control over financial reporting, including improving segregation of duties and review processes.

Key Dates

Recommendation

The company's severe financial distress, including recurring significant losses, a substantial working capital deficit, and an explicit 'going concern' warning from its auditors, presents a high-risk investment profile. The recent Nasdaq delisting further compounds liquidity and investor confidence issues. While the new committed equity facility offers a potential lifeline, its proceeds are primarily allocated to highly volatile Bitcoin purchases, introducing extreme and unpredictable risk to the balance sheet. The core products are still in early commercialization or clinical trial stages with no guaranteed timely regulatory approval or widespread market acceptance. Existing debt defaults and the overall high-risk profile suggest significant near-term downside potential, making it an unfavorable investment for seasoned investors or institutions at this time.

Keywords

Biointegrated Sensors, Continuous Glucose Monitoring, Lumee Oxygen Platform, Lumee Glucose Platform, Medical Devices, Healthcare Technology, SEC Filing, Committed Equity Facility, Bitcoin Treasury Strategy, Dilution, Going Concern, Clinical Trials, Regulatory Approval, Intellectual Property, Nasdaq Delisting, SPAC Merger, Patient Monitoring, Chronic Conditions, Diabetes Management, Wound Care, Biomarkers, Telemedicine, Health and Wellness